Open Access

Restriction beyond the restriction point: mitogen requirement for G2 passage

Cell Division20061:8

https://doi.org/10.1186/1747-1028-1-8

Received: 14 May 2006

Accepted: 18 May 2006

Published: 18 May 2006

Abstract

Cell proliferation is dependent on mitogenic signalling. When absent, normal cells cannot pass the G1 restriction point, resulting in cell cycle arrest. Passage through the G1 restriction point involves inactivation of the retinoblastoma protein family. Consequently, loss of the retinoblastoma protein family leads to loss of the G1 restriction point. Recent work in our lab has revealed that cells possess yet another mechanism that restricts proliferation in the absence of mitogens: arrest in the G2 phase of the cell cycle. Here, we discuss the similarities and differences between these restriction points and the roles of cyclin-dependent kinase inhibitors (CKIs) herein.

Introduction

During each division cycle, cells need to duplicate their genome and distribute the two copies equally over the two daughter cells. The processes of DNA-duplication (S-phase) and cell division (mitosis) are separated by two gap phases, G1 and G2, respectively. During these phases, several mechanisms operate to prevent cells from continuing the cell cycle under inappropriate conditions such as the absence of growth factors or the presence of DNA damage. The gap phases provide a window of time during which cells assess whether the environment still favours proliferation (during G1) or whether S-phase was performed correctly (during G2). If this is not the case, normal cells can interrupt the cell cycle in the gap phases through growth inhibitory mechanisms that activate the retinoblastoma proteins or the p53 transcription factor. In cancer cells, these growth inhibitory pathways are often disrupted, leading to unscheduled proliferation[1].

The G1 restriction point

One critical environmental factor for cell proliferation is the presence of growth factors and normal cells respond to their absence with cell cycle arrest in G1. However, during the G1 phase, growth factors are only required until 2–3 hours prior to initiation of S-phase[2]. This moment in G1 was first described in 1974 by Arthur Pardee and termed the restriction point R. Pardee found that cells that have passed the G1 restriction point can progress through S-phase and complete mitosis independently of mitogens[3]. Since entry into S-phase after growth factor induction was found to rely on protein synthesis, it was suggested that cells need to accumulate a protein in order to pass the restriction point[4]. This hypothetical protein was referred to as the R-protein, and is apparently induced by mitogens. Importantly, Pardee found that the restriction point was defective in cancer cell lines, providing physiological relevance for the restriction point. In addition, cancer cells were much more resistant to inhibition of protein synthesis, suggesting that the R-protein was either stabilized in these cells or not required[5]. The transformed cell lines that were used in this study carried simian virus 40 (SV40)[2]. The finding that the oncogenic products of DNA tumor viruses, such as SV40 large T antigen, adenovirus E1A and HPV E7, disrupt G1/S control through their inhibitory interaction with the retinoblastoma gene product[6, 7], provided a crucial link to the machinery underlying the restriction point.

The retinoblastoma gene encodes a 105 kD nuclear phosphoprotein (pRB) that in its unphosphorylated state can bind to and repress E2F transcription factors whose activity is essential for G1/S transition [812]. Since pRB is dephosphorylated late in mitosis by PP1 phosphatase[13], it needs to be phosphorylated during G1 to allow entry into S-phase and this requires mitogenic signalling. Mitogenic signalling results in increased transcription and stabilization of CYCLIN D [14], which stimulates its catalytic partners CDK4 and CDK6 to phosphorylate pRB early in G1, causing partial inactivation of pRB and release of E2F[15]. E2F transcription factor activity results in increased transcription of several genes involved in cell cycle progression among which CYCLIN E. CYCLIN E/CDK2 activity phosphorylates pRB to a higher extent, triggering full release of E2F and onset of S-phase. Conversely, in the absence of mitogens, decreased transcription of CYCLIN D1 and decreased stability of CYCLIN D1 protein favor the pRB unphosphorylated state, which inhibits E2F activity and causes cell cycle arrest in G1. Additionally, mitogen deprivation causes accumulation of the cyclin dependent kinase inhibitor (CKI) p27KIP1 through activation of the FOXO transcription factor[16, 17]. p27KIP1 is a potent inhibitor of CYCLIN E/CDK2 kinase activity[18], and will therefore prevent inactivation of pRB.

Somewhat unexpectedly, Rb-deficient mouse embryonic fibroblasts (MEFs) still arrested in G1 when mitogen starved, although a small fraction of the cells could enter S-phase[19, 20]. This has been explained by the activity of two other retinoblastoma protein family members, p130 and p107, which have redundant functions in regulating E2F transcription factors[21]. Together, these proteins make up the so-called family of pocket proteins, which refers to their highly conserved 'pocket-region' that is essential for interacting with E2Fs[10, 22, 23]. Indeed, MEFs that have lost all three pocket proteins are no longer capable of arresting in G1 when mitogen starved[24, 25].

The retinoblastoma proteins can thus be seen as molecular switches that operate at the restriction point: when switched -off- by mitogens, they allow passage through the restriction point and initiation of S-phase, while the -on- state results in cell cycle arrest. The downstream target of the switches are the E2F transcription factors, whose activity results S-phase entry[12]. The switches are operated by cyclin-associated kinase activities in G1 that can be modulated by the stability of the cyclin subunit, as is the case for CYCLIN D, or by inhibition of the kinase activity, as is the case for CYCLIN E/CDK2. CYCLIN D has been suggested as an appropriate candidate for the R-protein[26], since it is dependent on mitogens for its synthesis, is destabilized in the absence of mitogens and operates the 'molecular switch'. However, ablation of all three CYCLIN D family members (Cyclin D1, D2 and D3) did not block re-stimulation of serum-arrested cells (i.e., 60–80% of the cells were able to re-enter the cell cycle when stimulated with 10% serum)[27]. In contrast, MEFs in which both CYCLIN E family members (CYCLIN E1 and E2) were ablated, failed to re-enter the cell cycle after mitogen deprivation due to failure in loading MCM proteins to the DNA, which is essential for S-phase initiation[28, 29]. Since CYCLIN E accumulates during G1 and its ablation results in failure of cell cycle re-entry, CYCLIN E may be a good candidate for the R-protein[30].

Mitogen dependence of Rb/p107/p130-deficient MEFs

Pardee originally suggested that once cells have passed the restriction point, the cell cycle can proceed independently of mitogens until mitosis[2]. Accordingly, ablation of the retinoblastoma gene family, resulting in complete loss of the G1 restriction point[24, 25], should allow mitogen-independent proliferation. However, this was shown not to be the case: pocket-protein deficient cells are prevented from entering mitosis in the absence of mitogens by two mechanisms: (1) the majority of cells undergoes apoptosis[24, 25, 31]; (2) surviving cells arrest in the G2 phase of the cell cycle within 3–5 days[31]. Apparently, mitogenic signaling is not only required for passing the G1 restriction point, but also for passage through G2. While activation of the G1 restriction point in normal cells involves inhibition of D- and E-type cyclins, mitogen-starvation-induced G2 arrest is effected by accumulation of p27KIP1 and p21CIP1 that act as inhibitors of CYCLIN B1- and CYCLIN A-associated kinase activities[31].

CKI mediated inhibition of CDK1, the catalytic partner of CYCLIN B1, has been described in other systems as well. In addition to its CDK2-inhibiting activity[32], p21CIP1 was shown to induce a G2 arrest upon DNA damage[33] or upon over-expression[34] by inhibiting CDK1 kinase activity through direct interaction. In contrast to an earlier report[18], recent work from several laboratories has revealed that also p27KIP1 can inhibit CDK1 kinase activity through direct interaction. E.g., p27KIP1 is highly expressed in thymocytes and splenocytes and binds to and inhibits CYCLIN B1-CDK1 kinase activity in these cells[35]. In mice, ablation of SKP2, an F-Box protein that targets p27KIP1 to an SCF ubiquitin-ligase complex, resulted in elevated p27KIP1 levels associated to CDK1. Most defects in these animals are the result of decreased CDK1 and CDK2 kinase activities and can be rescued by concomitant ablation of p27KIP1, which restores physiological cyclin-dependent kinase activities[36].

G2 arrest: a second restriction point?

The mitogen-starvation-induced G2 arrest shows several similarities to the G1 restriction point. E.g., both depend on inhibition of cyclin-associated kinase activities and in both, accumulation of p27KIP1 plays an important (although not exclusive) role[31]. Importantly, both are reversible: mitogen stimulation of G2-arrested pocket-protein-deficient cells results in reactivation of the cell cycle and synchronous entry into mitosis after approximately 15 hours. Is there also a true restriction point in G2 in the sense that a time point can be identified after which cells do no longer require serum to enter mitosis? To address this issue, we serum-starved pocket-protein deficient MEFs for 7 days, and then re-fed the cells with serum-containing medium at time point 0. At several time points hereafter, we replaced the serum-containing medium for serum-free medium. To quantify G2 exit, we trapped the cells in mitosis using the microtubule-stabilizing drug Taxol. 21 hours after serum-stimulation, we harvested the cells and determined the mitotic fraction by FACS-staining for the mitotic marker MPM2 as described previously[31]. Figure 1A shows that the fraction of cells entering mitosis gradually increased upon longer duration of serum exposure. However, at 6 hours of serum exposure, the maximum amount of mitotic cells was reached. This indicates that mitogen-starved G2 arrested cells only required a window of 3–6 hours of serum in order to re-enter the cell cycle, identifying a G2 restriction point at approximately 10 hours before mitotic entry.
Figure 1

Evidence for a G 2 restriction point. A. Cell cycle re-entry from G2 requires 6 hours of mitogen-stimulation. Serum-starved cells were stimulated by the addition of serum-containing medium. Subsequently, at the indicated times medium was replaced with serum-free medium containing Taxol for the last 9 hours. At 21 hours cells were harvested and fixed in 70% ethanol and mitotic entry was determined by MPM2 FACS staining. Error bars indicate the standard deviation for two experiments. B. Cell cycle re-entry from G2 requires protein synthesis. Serum-starved cells were serum-stimulated in the absence or presence of 50 μg/ml cycloheximide (CHX). Cells were fixed at 21 hours and mitotic entry was determined by MPM2 FACS staining. The level of MPM2 positivity in serum-stimulated cells at 21 hours is set at 100%.

Next, we wondered whether cell cycle re-entry of serum-starved G2-arrested cells relies on protein translation, as was previously shown for recovery from G1 arrest. We therefore compared serum stimulation of G2-arrested cells in the presence and absence of the translation inhibitor cycloheximide. Figure 1B shows that inhibition of protein synthesis precluded cell cycle re-entry of serum-stimulated cells. This suggests that passage through the G2 restriction, like passage through the G1 restriction point, depends on synthesis of one or multiple proteins.

An important question now is: why was the G2 restriction point not identified in the original experiments of Pardee? A first explanation is that activation of pocket proteins in serum-starved normal cells (i.e., wild type MEFs) imposes an arrest in G1 that largely prevents subsequent cell cycle events. However, if cells possess two restriction points, and mitogen deprivation results in inhibition of all cyclin-associated kinase activities, why then do normal cells mainly arrest in G1 and is G2 arrest only seen in pocket-protein compromised MEFs? One reason could be that the levels of suppression of CYCLIN/CDK activity required for G1 or G2 arrest are different. In wild type cells, minor inhibition of D- and E-type cyclins may already impose a G1 arrest through accumulation of hypophosphorylated pocket proteins. In contrast, G2 arrest imposed by inhibition of CYCLIN A- and B kinase activities requires high levels of p21CIP1 and p27KIP1, which need several days to accumulate. Apparently, when these levels are reached in pocket-protein-deficient cells, the remaining CDK2 kinase activity is still sufficient to drive cells through S-phase, while the remaining CDK1 activity is too low to allow entry into mitosis, resulting in G2 arrest.

Secondly, G2 arrest in serum-starved, pocket-protein defective cells relies on functional p53[31]. The cancer cell line that was used for the original experiments contained SV40 Large T antigen, which inactivates the pocket proteins, but also p53[37]. Therefore, both the G1 and the G2 restriction points were inactivated in these cells.

Conclusion

The G1 restriction point defines a window of mitogen requirement in G1. However, in the absence of pocket protein activity, another growth-restricting mechanism in G2 becomes manifest that prevents unconstrained proliferation under mitogen-starved conditions. This G2 arrest has the following features:
  1. 1.

    It allows cell cycle progression only in the presence of mitogens.

     
  2. 2.

    It is reversible: mitogen-starved, G2-arrested cells re-enter the cell cycle synchronously upon mitogen stimulation.

     
  3. 3.

    A specific moment in G2 exists, approximately 10 hours before mitotic entry, after which cells can progress into mitosis independently of mitogens.

     
  4. 4.

    Recovery from G2 arrest relies on accumulation of one or multiple proteins.

     
  5. 5.

    The G2 arrest is effectuated by inhibition of CYCLIN-CDK activity through association with CKIs.

     

These properties of serum-starvation induced G2 arrest identify a true restriction point in G2. However, the G1 and G2 restriction points are not completely identical at the molecular level. For one: whereas the G1 restriction point critically depends on the activity of the pocket proteins, the G2 restriction point only becomes manifest when pocket protein activity is diminished or absent. Furthermore, the G1 restriction point involves degradation of CYCLIN D in addition to CKI-mediated inhibition of CYCLIN E, whereas the G2 restriction point appears to rely solely on CKI-mediated inhibition of CYCLIN A- and CYCLIN B- associated kinase activities.

Taken together, we postulate that cells possess two restriction points defining the requirement for mitogenic signaling in G1 and in G2 to stimulate CYCLIN D/E and CYCLIN A/B kinase activities, respectively (Fig. 2A). In both, accumulation of p27KIP1 plays an important role. When growth factors are removed from normal cells, rapid disappearance of CYCLIN D1 and inhibition of CYCLIN E by accumulation of p27KIP1 results in hypophosphorylated pRB, low E2F activity and G1 arrest (Fig. 2B). In cells that have lost the pocket proteins and hence the G1 restriction point, the G2 restriction point comes into play. Accumulation of p21CIP1 and p27KIP1 apparently leaves sufficient CDK2 activity to allow cells to cross the G1/S border and complete S phase (likely because of elevated E2F activity in the absence of pocket proteins). However, inhibition of CYCLIN A- and B kinase activity now arrests cells in G2 (Fig. 2C).
Figure 2

Extending the restriction point. A. Cell cycle progression is dependent on CYCLIN-CDK kinase activity. B. Mitogen starvation results in cell cycle arrest in G1 through degradation or suppression of CYCLIN D and CKI-mediated inhibition of CYCLIN E-CDK2. C. Unscheduled passage through the G1 restriction point in the absence of mitogens (e.g., through RB loss) results in cell cycle arrest in G2.

We envisage that the G2 restriction point serves as a backup mechanism to prevent unconstrained proliferation of cells that have lost proper G1/S control. Indeed, a substantial amount of circumstantial evidence suggests a role for the G2 restriction point in the suppression of cancer[38]. E.g., it is possible that tumor cells in a primary tumor retain a normal G2 arrest that does not perturb proliferation at the site of origin but only becomes activated under special conditions such as dissemination to distant sites. Indeed, occult, non-proliferating tumor cells that were found in the bone marrow and bloodstream of cancer patients without overt metastases, may present an example of this scenario[39]. Elucidation of the mechanism of cell cycle arrest is of paramount importance to control the behavior of such cells.

Abbreviations

MEFs: 

mouse embryonic fibroblasts

CKI: 

cyclin dependent kinase inhibitor

FCS: 

fetal calf serum.

Declarations

Acknowledgements

We want to thank Marieke Aarts, Daniel Peeper, Tinke Vormer, Camiel Wielders and Rob Wolthuis for their comments on the manuscript and the members of the Te Riele lab for fruitful discussions. We are grateful to the Dutch Cancer Society for financially supporting our work on cell cycle control (NKI 2000-2232, NKI 2002-2634).

Authors’ Affiliations

(1)
Division of Molecular Biology, the Netherlands Cancer Institute

References

  1. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100: 57–70. 10.1016/S0092-8674(00)81683-9PubMedView ArticleGoogle Scholar
  2. Pardee AB: A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci U S A 1974, 71: 1286–1290.PubMed CentralPubMedView ArticleGoogle Scholar
  3. Sherr CJ, Roberts JM: Living with or without cyclins and cyclin-dependent kinases. Genes Dev 2004, 18: 2699–2711. 10.1101/gad.1256504PubMedView ArticleGoogle Scholar
  4. Rossow PW, Riddle VG, Pardee AB: Synthesis of labile, serum-dependent protein in early G1 controls animal cell growth. Proc Natl Acad Sci U S A 1979, 76: 4446–4450.PubMed CentralPubMedView ArticleGoogle Scholar
  5. Campisi J, Medrano EE, Morreo G, Pardee AB: Restriction point control of cell growth by a labile protein: evidence for increased stability in transformed cells. Proc Natl Acad Sci U S A 1982, 79: 436–440.PubMed CentralPubMedView ArticleGoogle Scholar
  6. Pardee AB: G1 events and regulation of cell proliferation. Science 1989, 246: 603–608.PubMedView ArticleGoogle Scholar
  7. Munger K, Phelps WC, Bubb V, Howley PM, Schlegel R: The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. J Virol 1989, 63: 4417–4421.PubMed CentralPubMedGoogle Scholar
  8. Lundberg AS, Hahn WC, Gupta P, Weinberg RA: Genes involved in senescence and immortalization. Curr Opin Cell Biol 2000, 12: 705–709. 10.1016/S0955-0674(00)00155-1PubMedView ArticleGoogle Scholar
  9. Harbour JW, Luo RX, Dei Santi A, Postigo AA, Dean DC: Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1. Cell 1999, 98: 859–869. 10.1016/S0092-8674(00)81519-6PubMedView ArticleGoogle Scholar
  10. Harbour JW, Dean DC: The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000, 14: 2393–2409. 10.1101/gad.813200PubMedView ArticleGoogle Scholar
  11. Ezhevsky SA, Ho A, Becker-Hapak M, Davis PK, Dowdy SF: Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo. Mol Cell Biol 2001, 21: 4773–4784. 10.1128/MCB.21.14.4773-4784.2001PubMed CentralPubMedView ArticleGoogle Scholar
  12. Wu L, Timmers C, Maiti B, Saavedra HI, Sang L, Chong GT, Nuckolls F, Giangrande P, Wright FA, Field SJ, Greenberg ME, Orkin S, Nevins JR, Robinson ML, Leone G: The E2F1–3 transcription factors are essential for cellular proliferation. Nature 2001, 414: 457–462. 10.1038/35106593PubMedView ArticleGoogle Scholar
  13. Ludlow JW, Glendening CL, Livingston DM, DeCarprio JA: Specific enzymatic dephosphorylation of the retinoblastoma protein. Mol Cell Biol 1993, 13: 367–372.PubMed CentralPubMedView ArticleGoogle Scholar
  14. Malumbres M, Barbacid M: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001, 1: 222–231. 10.1038/35106065PubMedView ArticleGoogle Scholar
  15. Planas-Silva MD, Weinberg RA: The restriction point and control of cell proliferation. Curr Opin Cell Biol 1997, 9: 768–772. 10.1016/S0955-0674(97)80076-2PubMedView ArticleGoogle Scholar
  16. Coats S, Flanagan WM, Nourse J, Roberts J: Requirement of p27Kip1 for Restriction Point Control of the Fibroblast Cell Cycle. Science 1996, 272: 877–880.PubMedView ArticleGoogle Scholar
  17. Medema RH, Kops GJ, Bos JL, Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000, 404: 782–787. 10.1038/35008115PubMedView ArticleGoogle Scholar
  18. Toyoshima H, Hunter T: p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994, 78: 67–74. 10.1016/0092-8674(94)90573-8PubMedView ArticleGoogle Scholar
  19. Herrera RE, Sah VP, Williams BO, Makela TP, Weinberg RA, Jacks T: Altered cell cycle kinetics, gene expression, and G1 restriction point regulation in Rb-deficient fibroblasts. Mol Cell Biol 1996, 16: 2402–2407.PubMed CentralPubMedView ArticleGoogle Scholar
  20. Almasan A, Yin Y, Kelly RE, Lee EY, Bradley A, Li W, Bertino JR, Wahl GM: Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc Natl Acad Sci U S A 1995, 92: 5436–5440.PubMed CentralPubMedView ArticleGoogle Scholar
  21. Mulligan G, Jacks T: The retinoblastoma gene family: cousins with overlapping interests. Trends Genet 1998, 14: 223–229. 10.1016/S0168-9525(98)01470-XPubMedView ArticleGoogle Scholar
  22. Chow KN, Dean DC: Domains A and B in the Rb pocket interact to form a transcriptional repressor motif. Mol Cell Biol 1996, 16: 4862–4868.PubMed CentralPubMedView ArticleGoogle Scholar
  23. Lipinski MM, Jacks T: The retinoblastoma gene family in differentiation and development. Oncogene 1999, 18: 7873–7882. 10.1038/sj.onc.1203244PubMedView ArticleGoogle Scholar
  24. Dannenberg JH, van Rossum A, Schuijff L, te Riele H: Ablation of the retinoblastoma gene family deregulates G(1) control causing immortalization and increased cell turnover under growth-restricting conditions. Genes Dev 2000, 14: 3051–3064. 10.1101/gad.847700PubMed CentralPubMedView ArticleGoogle Scholar
  25. Sage J, Mulligan GJ, Attardi LD, Miller A, Chen S, Williams B, Theodorou E, Jacks T: Targeted disruption of the three Rb-related genes leads to loss of G(1) control and immortalization. Genes Dev 2000, 14: 3037–3050. 10.1101/gad.843200PubMed CentralPubMedView ArticleGoogle Scholar
  26. Blagosklonny MV, Pardee AB: The restriction point of the cell cycle. Cell Cycle 2002, 1: 103–110.PubMedGoogle Scholar
  27. Kozar K, Ciemerych MA, Rebel VI, Shigematsu H, Zagozdzon A, Sicinska E, Geng Y, Yu Q, Bhattacharya S, Bronson RT, Akashi K, Sicinski P: Mouse development and cell proliferation in the absence of D-cyclins. Cell 2004, 118: 477–491. 10.1016/j.cell.2004.07.025PubMedView ArticleGoogle Scholar
  28. Geng Y, Yu Q, Sicinska E, Das M, Schneider JE, Bhattacharya S, Rideout WM, Bronson RT, Gardner H, Sicinski P: Cyclin E ablation in the mouse. Cell 2003, 114: 431–443. 10.1016/S0092-8674(03)00645-7PubMedView ArticleGoogle Scholar
  29. Parisi T, Beck AR, Rougier N, McNeil T, Lucian L, Werb Z, Amati B: Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells. EMBO J 2003, 22: 4794–4803. 10.1093/emboj/cdg482PubMed CentralPubMedView ArticleGoogle Scholar
  30. Dou QP, Levin AH, Zhao S, Pardee AB: Cyclin E and cyclin A as candidates for the restriction point protein. Cancer Res 1993, 53: 1493–1497.PubMedGoogle Scholar
  31. Foijer F, Wolthuis RM, Doodeman V, Medema RH, te Riele H: Mitogen requirement for cell cycle progression in the absence of pocket protein activity. Cancer Cell 2005, 8: 455–466. 10.1016/j.ccr.2005.10.021PubMedView ArticleGoogle Scholar
  32. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ: The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993, 75: 805–816. 10.1016/0092-8674(93)90499-GPubMedView ArticleGoogle Scholar
  33. Baus F, Gire V, Fisher D, Piette J, Dulic V: Permanent cell cycle exit in G2 phase after DNA damage in normal human fibroblasts. EMBO J 2003, 22: 3992–4002. 10.1093/emboj/cdg387PubMed CentralPubMedView ArticleGoogle Scholar
  34. Medema RH, Klompmaker R, Smits VA, Rijksen G: p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 1998, 16: 431–441. 10.1038/sj.onc.1201558PubMedView ArticleGoogle Scholar
  35. Aleem E, Kiyokawa H, Kaldis P: Cdc2-cyclin E complexes regulate the G1/S phase transition. Nat Cell Biol 2005, 7: 831–836. 10.1038/ncb1284PubMedView ArticleGoogle Scholar
  36. Nakayama K, Nagahama H, Minamishima YA, Miyake S, Ishida N, Hatakeyama S, Kitagawa M, Iemura S, Natsume T, Nakayama KI: Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 2004, 6: 661–672. 10.1016/S1534-5807(04)00131-5PubMedView ArticleGoogle Scholar
  37. Ahuja D, Saenz-Robles MT, Pipas J: SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation. 24: 7729–7745.Google Scholar
  38. Foijer F, te Riele H: Check, double check: the g(2) barrier to cancer. Cell Cycle 2006, 5: 831–836.PubMedView ArticleGoogle Scholar
  39. Muller V, Stahmann N, Riethdorf S, Rau T, Zabel T, Goetz A, Janicke F, Pantel K: Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity. Clin Cancer Res 2005, 11: 3678–3685. 10.1158/1078-0432.CCR-04-2469PubMedView ArticleGoogle Scholar

Copyright

© Foijer and te Riele; licensee BioMed Central Ltd. 2006

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.